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BACKGROUND AND PURPOSE
A common site for drug binding on voltage-gated ion channels is at the interior face of the channel pore. In this study, we
tested the hypothesis that the extent of drug block of the human cardiac KCNA5 (Kv1.5) channel underlying the
atrial-specific, ultra-rapidly activating, delayed K+ current (IKur) is modulated by the drug uptake and efflux transporters
encoded by organic cation transporter 1 (OCTN1) and multiple drug-resistant gene 1 (MDR1) and expressed in human heart.

EXPERIMENTAL APPROACH
Drug block of KCNA5 was assessed in Chinese hamster ovary cells transiently transfected with KCNA5 alone or in combination
with the OCTN1 or MDR1 transporter construct, as well as in an MDR1 stably expressed cell line.

KEY RESUTLS
Co-expression of OCTN1 significantly facilitated block by quinidine (10 mM), verapamil (20 mM), propafenone (5 mM) and
clofilium (30 mM). Further evidence of drug transport modulating drug block was the finding that with OCTN1, block
developed faster and only partially washed-out, and that block potentiation was prevented by cimetidine, an inhibitor of
OCTN1. MDR1 expression attenuated KCNA5 block by erythromycin (an MDR1 substrate). Block was restored by reversin-205
(10 mM, an MDR1 inhibitor). MDR1 did not affect KCNA5 inhibition by KN-93 (1 mM), a blocker acting on the outer mouth
of the channel pore.

CONCLUSIONS AND IMPLICATIONS
The extent of drug block of KCNA5 can be modulated by drug uptake and efflux transporters. These data provide further
support for the idea that modifying intracellular drug concentrations could modulate the effects of blocking ion channels in
patients.

Abbreviations
4-AP, 4-aminopyridine; ABCB1, multiple drug-resistant gene 1 (MDR1); CHO, Chinese hamster ovary cells; GFP, green
fluorescent protein; KCNA5, gene encoding the ultra-rapid outward rectifying K+ current (IKur); OCTN1, organic cation
transporter 1; P-gp, P-glycoprotein
© 2010 The Authors
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Introduction

Methods

Atrial fibrillation (AF) is the most common sustained cardiac tachyarrhythmia for which drug
therapy is prescribed, and affects approximately 2–5
million patients in the United States and developed
countries (Hylek et al., 2001; Fuster et al., 2006;
Thom et al., 2006). One approach to therapy
involves increasing myocardial refractoriness by
block of atrial repolarizing currents carried by K+
channels, such as the delayed repolarizing current
IKr (current and channel nomenclature follows Alexander et al., 2009). However, block of IKr also prolongs refractoriness in the ventricle leading to the
lethal arrhythmia Torsade de pointes. An atrialspecific and ultra-rapidly activated potassium
current (IKur), encoded by the gene KCNA5 (Kv1.5),
has been detected in humans (Wang et al., 1993; Li
et al., 1996; Nattel et al., 1999). Native cardiac IKur
displays similar biophysical and pharmacological
profiles to those observed with heterologous
expression of cloned Kv1.5 channels: for example,
voltage-dependent rapid activation, slow/partial
inactivation and sensitivity to several blocking
agents, such as quinidine and 4-aminopyridine
(4-AP) (Snyders et al., 1993; Yeola et al., 1996). Since
IKur is specifically present in human atrial cells, selective block of IKur has been suggested as a target for
development of drugs against AF (Savelieva and
Camm, 2008a; Ehrlich and Nattel, 2009; Milan
et al., 2009).
For many ion channels, including KCNA5, the
drug-binding site is located on the intracellular face
of the channel pore (Mitcheson et al., 2000; Chen
et al., 2002; Seebohm et al., 2003; Decher et al.
2004). This finding suggests the hypothesis that
inter-patient variability in drug block may in part
reflect variable drug uptake/influx into or efflux
from intracellular molecular effector sites. Studies by
us and others have demonstrated that many drug
influx and efflux transporters are present in human
heart (Grube et al., 2006; Iwata et al., 2008; McBride
et al., 2009a,b). We have recently shown that drug
block of the KCNH2 potassium channel (responsible
for cardiac IKr) can be modulated by co-expression of
the drug uptake transporter organic cation transporter 1 (OCTN1) and variants of multiple drugresistant gene 1 (MDR1), encoding the efflux
transporter P-glycoprotein (P-gp) (McBride et al.,
2009a,b). In the present study, we have extended
these findings to study the modulating effects of
OCTN1 and MDR1 co-expression on the degree of
drug block of a second K+ channel, KCNA5. In addition, we show that the extent of drug block in these
settings can be modulated by inhibitors of transporter function.

FuGENE6-mediated KCNA5 channel
expression

1024 British Journal of Pharmacology (2010) 161 1023–1033

Recombinant cDNA for the human cardiac KCNA5
(Kv1.5) channel was transiently transfected in
Chinese hamster ovary (CHO) cells. The cells lack
endogenous outward currents and are thus suitable
for K+ current studies. The cells were grown to confluence in F-12 nutrient mixture (HAM) medium
(Invitrogen, Carlsbad, CA, USA) supplemented with
10% horse serum, 2 mM L-glutamine and penicillin
(50 U·mL-1)-streptomycin (50 mg·mL-1) at 37°C.
Cells were transiently transfected with wild-type
KCNA5 in a pBK/CMV vector (Stratagene, Santa
Clara, CA, USA) with a pIRES-green fluorescent
protein (GFP) bi-cistronic expression vector containing either an empty vector site (control), wild-type
OCTN1 or MDR1 (isoform ABCB1*7). The ration of
Fugene6 to cDNA plasmids was 2 mg:2 mg:12 mL. The
cells were subsequently removed from the dish by
brief trypsinization, and stored in standard medium
for the experiments within the next 12 h. Cells
showing green fluorescence by enhanced green fluorescent protein (eGFP) were chosen to identify successfully transfected cells for the voltage-clamp
analysis. In some experiments, a pig kidney epithelial cell line, stably expressing MDR1 (L-MDR cells),
was also used for transfections with KCNA5-eGFP
construct to investigate the effects of endogenous
MDR1 and its inhibitor (reversin-205) on KCNA5
block by erythromycin and KN-93.

Whole-cell voltage clamp
KCNA5 current was recorded in the whole-cell configuration of the patch-clamp technique using an
Axopatch 200B amplifier (Axon Instruments Inc,
Foster City, CA, USA). Patch pipettes were pulled
from thick-wall borosilicate glass (World Precision
Instruments, Inc., Sarasota, FL, USA) with a multistage P-97 Flaming-Brown micropipette puller
(Sutter Instruments Co., Novato, CA, USA) and firepolished. Pipette resistance was 2–4 mW. Whole-cell
current traces were filtered at 5 kHz and acquired at
1 to 2 kHz. To obtain current–voltage (I-V) relations,
the holding potential was –80 mV. Activating currents were elicited with 500 ms depolarizing pulses
from –40 to +60 mV in 10 mV steps, and tail currents for another 500 ms were recorded upon return
to –40 mV. Pulses were delivered at every 15 s interval. Other specific voltage-clamp protocols are presented as insets in figures.
After collection of baseline data, individual drugs
were added to the perfusate while pulsing continued. Prior to and during drug exposure, KCNA5
current was dynamically monitored by using
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500 ms pulses to +50 mV from a holding potential
of –80 mV, delivered at a frequency of 5 kHz. Pulse
generation, data acquisition and analyses were
accomplished using Clampex/Clampfit version 9.2
(Axon Instruments, Inc). Current densities (in
pA/pF) were obtained after normalization to cell
surface area. The I–V relationships were determined
by fitting data to the Boltzmann equation: I = Imax/{1
+ exp[(Vt - V1/2)/k]}, where Imax was for the maximal
current, Vt for the testing potential, V1/2 for the
membrane potential at which 50% of the channels
were activated and k for the slope factor. Time constants for activation and deactivation were obtained
by mono-exponentially fitting the currents to a
Chebyshev equation with CLAMPFIT software. Furthermore, the concentration–response curves for
quinidine block were determined in the absence and
presence of OCTN1 to calculate an IC50 value, the
concentration required to inhibit 50% of the
channel current. All experiments were conducted at
22–23°C.

Solutions
To record Kv1.5 current, the internal pipette filling
solution contained (in mM): KCl 110, K4BAPTA 5,
K2ATP 5, MgCl2 1 and HEPES 10. The solution was
adjusted to pH 7.2 with KOH, yielding a final [K+]i of
~145 mM. The external solution was normal
Tyrode’s, containing (in mM) NaCl 130, KCl 4,
CaCl2 1.8, MgCl2 1, HEPES 10 and glucose 10, and
was adjusted to pH 7.35 with NaOH.

Statistical analysis

Data are expressed as mean ⫾ SEM. For comparisons
among means of more than two groups, ANOVA was
used, with post hoc pairwise comparisons by Duncan’s test if significant differences among means
were detected. If only two groups were being compared, Student’s t-test was used. A P-value < 0.05 was
considered statistically significant.

Materials
All chemicals and drugs in this study were purchased from Sigma-Aldrich, Inc. (St. Louis, MO,
USA). The drug concentrations used were close to
the published IC50 values, and in some experiments,
a range of concentrations was used. Drugs used in
this study included: quinidine (10 mM), verapamil
(20 mM), clofilium (30 mM), propafenone (5 mM),
4-AP (200 mM), erythromycin (200 mM) and KN-93
(1 mM). In experiments with the MDR1 inhibitor
reversin-205 (10 mM), the agent was added to cell
culture medium for 48 h prior to electrophysiological studies.

BJP

Results
The drug influx transporter OCTN1
potentiates block of KCNA5 channel by
several drugs

In the absence of any drug transporters, we first
tested five known KCNA5 blockers in our system at
or near concentrations reported to suppress IKur by
50%, as described above. Some of these drugs (quinidine and verapamil) have also been tested and
found to be OCTN1 substrates (Lee and Kim, 2004).
In experiments to assess drug trapping in the
channel pore, quinidine was used at a high concentration of 100 mM to obtain a maximal block. The
blocking effects of each drug were then compared to
those in cells transfected with KCNA5 + OCTN1
plasmid(s).
Figure 1A shows the characteristics of the wildtype KCNA5 current: fast activation, slightly slow
inactivation by using a voltage clamp protocol from
a holding potential of –80 mV to +60 mV with
500 ms depolarizing pulses at 10 mV steps. In separate experiments in which an equal amount of
OCTN1-eGFP plasmid was co-expressed with wildtype KCNA5 channel, the characteristics of KCNA5
current still remained unchanged (Figure 1B). There
are no statistically significant differences of the magnitudes of activating and deactivating currents in
the two groups of cells (Figure 1C). And the V1/2, the
membrane voltage at which the KCNA5 channel
was activated by 50%, was also unaltered: –12.9 ⫾
1.6 mV (-OCTN1, n = 7) versus –12.2 ⫾ 1.9 mV
(+OCTN1, P = NS, n = 8).
To further test our hypothesis that drug block of
the KCNA5 channel could be potentiated by the
drug uptake transporter OCTN1, we selected quinidine as a standard KCNA5 blocker to determine the
concentration–response curves in the absence and
presence of OCTN1. Cells were exposed to quinidine
at the concentrations of 1, 3, 10 and 30 mM in order.
As shown in Figure 1D and E, superimposed raw
current traces recorded with a single 500 ms pulse to
+50 mV from a holding potential of –80 mV demonstrate that co-expression of OCTN1 markedly
potentiated quinidine block of the KCNA5 current
in a concentration-dependent manner. A summary
of concentration–response curves is presented in
Figure 1F: the IC50 values for quinidine block were
7.8 ⫾ 0.9 mM (-OCTN1) versus 4.7 ⫾ 0.3 mM
(+OCTN1; n = 4–6 cells, P < 0.01).
Verapamil is an open state blocker of the KCNA5
channel (Rampe et al., 1993), as can be seen in
Figure 2B. Verapamil-induced block develops during
the depolarizing pulses, especially at more positive
potentials where open state probability of the
channel is increased. We found that with OCTN1
British Journal of Pharmacology (2010) 161 1023–1033
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Figure 1
Concentration-dependent block of KCNA5 channel by quinidine in the absence and presence of organic cation transporter 1 (OCNT1). Panel A
and B show that co-expression of OCTN1 did not alter the magnitude and gating of the KCNA5 current. Panel C is a summary of activating and
deactivating KCNA5 currents in the absence and presence of OCTN1. Panels D and E represent superimposed raw traces at +50 mV and, in F, the
concentration–response data for quinidine block of KCNA5 current in the absence and presence of OCTN1 co-expression. The voltage clamp
protocols are shown in insets. KCNA5, gene encoding the ultra-rapid outward rectifying K+ current (IKur).

expression, verapamil blocked KCNA5 current more
rapidly and completely (Figure 2E). Similar results
were observed with three other blocking drugs (clofilium, propafenone and 4-AP), and these data are
summarized in Figure 2C. These data demonstrate
that the drug uptake transporter OCTN1 potentiated the blocking action of several drugs on the
cardiac KCNA5 channel.
To further test the idea that this potentiation
represents enhanced transport of drug into the cytoplasm, we tested the effects of the H2-histamine
receptor antagonist cimetidine, which is also recognized as an OCTN1 inhibitor (Yabuuchi et al., 1999).
We first evaluated the effects of cimetidine (10 mM)
on IKur, and found <5% change in current amplitude
(Figure 2F). We next evaluated the effect of cimetidine pretreatment for 30 min on block by quinidine. As described above, 10 mM quinidine
1026 British Journal of Pharmacology (2010) 161 1023–1033

suppressed KCNA5 current by ~80% in the presence
of OCTN1 (Figure 2F). However, when cells expressing KCNA5 + OCTN1 were pretreated with cimetidine, the same concentration of quinidine reduced
current by ~50%, comparable to the effect seen in
the absence of OCTN1 co-expression (Figure 2C).
These results, summarized in Figure 2F, further
support our hypothesis that the transport function
of OCTN1 potentiated drug block of KCNA5
channels.

OCTN1 restricts KCNA5 channel recovery
from block
Given the results described above, we next examined the time course of recovery from block by quinidine in the absence and presence of the drug
uptake transporter OCTN1. We reasoned that when
drug block reached a steady state and then drug was
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Figure 2
Organic cation transporter 1 (OCTN1) potentiates KCNA5 block by several drugs. Panel A, B, D and E show representative traces prior to and
during verapamil (20 mM) in (–) or (+) OCTN1 co-expression for comparison. In the presence of OCNT1, verapamil block was faster in onset and
more complete. Panel C summarizes the effects of five KCNA5 blockers (quinidine, Qui; verapamil, Ver; clofilium, Clof; propafenone, Prop; 4-AP)
studied in (–) and (+) OCTN1 cells. Panel F shows that the pretreatment with cimetidine (10 mM, an OCTN1 inhibitor) prevented OCTN1 from
potentiating quinidine block, whereas cimetidine by itself had no effect on the current. KCNA5, gene encoding the ultra-rapid outward rectifying
K+ current (IKur).

withdrawn from the extracellular solution, the presence of an uptake transporter would result in slower
or incomplete loss of drug effect (since drug leaving
a cell would be more likely to undergo reuptake).
The pulse protocol we used is shown in Figure 3
(inset). The cells were repetitively stimulated with a
500 ms pulse to +50 mV from a holding potential of
–80 mV at 1 Hz. In the absence of OCTN1, 10 mM
quinidine reduced the steady-state KCNA5 current
by ~50% and block was fully reversible during
washout (Figure 3A/C). In the presence of OCNT1
co-expression, however, block by quinidine reached
>90% and recovery from block was incomplete
(~80%) with washout (Figure 3B/C). In addition,
the time constant for the onset of drug block in the
presence of OCTN1 was shorter than that in the
absence of OCTN1: 13 pulses (+OCTN1) versus 34
pulses (-OCTN1). Also, the time constants for

washout were 19 pulses (+OCTN1) versus 10 pulses
(-OCTN1). These data lend further support to the
idea that OTCN1-mediated drug uptake facilitates
quinidine block of the KCNA5 channel.
Figure 4 shows a second approach to further
probe recovery from drug block. We first applied a
pulse to +50 mV to record KCNA5 current and then
examined the time course of recovery from block at
the holding potential of –80 mV by varying the
inter-pulse interval from 1 to 20 s (Dt), followed by a
second pulse back to +50 mV for 100 ms to elicit the
current for recovery from block (the protocol is
shown in Figure 4D). In this way, dynamic changes
in drug block over time can be observed to determine whether recovery from block occurs as the
time to allow the channel to re-enter the closed state
is varied. In these experiments, we used a high concentration of quinidine (100 mM) which caused a
British Journal of Pharmacology (2010) 161 1023–1033
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Figure 3
Reversibility of quinidine block in the absence and presence of organic cation transporter 1 (OCTN1) co-expression. These experiments were
carried out by using repetitive pulses to +50 mV, shown as an insert. Panels A and B are traces at baseline, during drug exposure and during
washout (WO). Panel C shows the current changes over time in two groups of cells (n = 4 each), in which time constants for drug block onset
(T onset) and washout (T WO) are indicated.

high degree of block (~80%) even in the absence of
OCTN1 (Figure 4A). As expected, when OCTN1 was
co-expressed, this concentration of quinidine
reduced KCNA5 current >95% (Figure 4B). A
summary of the effect of 100 mM quinidine on the
KCNA5 current with and without OCTN1
co-expression is shown in Figure 4C: at +50 mV,
block was 97.3 ⫾ 2.4% (+OCTN1) versus 83.7 ⫾
2.1% (-OCTN1, P < 0.05, n = 7 each). By varying the
times at the holding potential (–80 mV), we could
observe partial recovery from block in the absence
of OCTN1 (Figure 4D): the current gradually
increased until it reached a new steady-state level.
However, with co-expression of OCTN1, the same
pulse protocol revealed almost no recovery from
block (Figure 4E). These results, summarized in
Figure 4F, imply that the presence of OCTN1 causes
an intracellular concentration of quinidine that prevents an observable recovery effect.

The drug efflux transporter MDR1 attenuates
drug block of the KCNA5 channel
We also studied the effects of co-expressing MDR1,
which encodes the drug efflux transporter P-gp, in
this study. We reasoned that a KCNA5 blocker which
is also a P-gp substrate would display reduced
1028 British Journal of Pharmacology (2010) 161 1023–1033

channel inhibition when the transporter was
co-expressed. To test this concept, we used erythromycin, which has been shown to be a P-gp substrate
(Sikri et al., 2004; Hariharan et al., 2009) and a
KCNA5 blocker (Rampe and Murawsky, 1997).
We first used repetitive 500 ms pulses to +50 mV
from a holding potential of –80 mV to define the
effects of 200 mM erythromycin (to generate
maximal block) with and without co-expression of
MDR1. As stated above, erythromycin inhibited
KCNA5 current acting as an open-channel blocker.
Without MDR1 co-expression, erythromycin
reduced the current rapidly and almost completely,
within the first 200 ms of pulsing (Figure 5A). Furthermore, block was only partially reversible by
washout. When MDR1 was co-expressed, however,
block by erythromycin was less and almost completely removed, with recovery of the current to the
basal level during washout (Figure 5B).
Figure 5C summarizes the degree of KCNA5
block by erythromycin (200 mM) in the absence and
presence of MDR1. MDR1 co-expression did not
affect basal KCNA5 current level. Without MDR1
co-expression, erythromycin markedly suppressed
the current at all test potentials. With MDR1 expression, however, a portion of the current remained

Drug transporters modulate drug block of cardiac KCNA5 channel

A

B

(-)OCTN1

C

(+)OCTN1

+50

baseline

baseline

-80

100 mM quinidine

20
000 pA

2000 pA

-40 mV

100 ms

100 ms

100 mM quinidine

KCNA5 block (%
%, +50 mV)

100

0.5 s

BJP
*

* 0 05 n=7
*p<0.05,
7 each
h

90
80
70
60
50
40
30
20
10
0

(-)OCTN1

(+)OCTN1

Quinidine (100 mM)

E

(-)OCTN1

F

(+)OCTN1

}Δ
0.1 s

+50

}Δ
20 ms

20 ms

(-)OCTN1
(+)OCTN1

14

500 pA

500 pA

0.5 s

100 mM quinidine

16

-40

Recovery from
m block
(D %, +50 mV)

D

12
10
8
6
4
2
0
0

Δt (s)

-80 mV

4

8

12

16

20

Time (sec)

Figure 4
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unblocked: for example, block at +50 mV was 91 ⫾
2% (-MDR1) versus 62 ⫾ 3% (+MDR1, P < 0.01, n =
7 each; Figure 5D). This is consistent with the idea
that MDR1 co-expression reduces intracellular drug
concentration, thereby attenuating drug block.

MDR1 inhibition restored block of KCNA5
channel by erythromycin, but not by KN-93
KN-93 is a channel blocker acting on the outer
mouth of the KCNA5 channel (Rezazadeh et al.,
2006). This compound also acts as a non-substrate
inhibitor of P-gp (Riganti et al., 2009). In the next
set of experiments, we examined the effects of erythromycin and KN-93 on KCNA5 channels with and
without 48 h pretreatment by reversin-205 (10 mM),
a membrane-permeable MDR1 inhibitor (Sharom

et al., 1999), in the absence and presence of MDR1
co-expression. These experiments were conducted
in both CHO and L-MDR1 cells, stably expressing
MDR1. Block by erythromycin in L-MDR1 cells was
identical to that in CHO cells with MDR1
co-expression (Figure 5D). In CHO cells transfected
with MDR1, reversin-205 pretreatment completely
restored erythromycin block to the level seen
without MDR1 co-expression (Figure 5D). Similarly,
when L-MDR1 cells were pretreated with reversin205, the extent of erythromycin block of the current
was very similar to those observed in (–)MDR1 and
(+)MDR1 + reversin in CHO cells (Figure 5D).
By contrast, KCNA5 block by KN-93 (1 mM),
which acts on KCNA5 channels from the extracellular aspect, was unaffected despite the dual inhibiBritish Journal of Pharmacology (2010) 161 1023–1033
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200 mM) in the absence of MDR1 co-expression. (B) Representative traces pre-/post-drug in the presence of MDR1 co-expression. (C) Summarized
data in four groups of cells (n = 7 each) with/without drug in the absence and presence of MDR1 co-expression. The voltage clamp protocol is
shown in the inset. (D) comparison of KCNA5 block by two drugs (200 mM erythromycin and 1 mM KN-93) in two types of cells [Chinese hamster
ovary cells (CHO) and L-MDR1] in the absence and presence of the MDR1 inhibitor reversin-205 (10 mM). *P < 0.01 versus (–)MDR1 or (+)reversin.
KCNA5, gene encoding the ultra-rapid outward rectifying K+ current (IKur).

tion of MDR1 by reversin-205 and KN-93 itself
(Figure 5D). Taken together, these data support the
idea that the efflux transporter P-gp decreases intracellular drug concentration and thereby reduces the
extent of block by drugs acting at intracellular sites
of action.

Discussion and conclusions
We and others have previously shown that drug
transporter proteins are expressed in heart and we
have shown that co-expression of influx or efflux
transporters modulates block of the rapid component of the cardiac delayed rectifier channel
(encoded by KCNH2) in heterologous expression
systems. The present study extends this work to
show that drug uptake and efflux transporters can
similarly modulate block of the KCNA5 channel,
which – like KCNH2 – includes a drug-binding/
blocking site on its intracellular aspect.
Atrial arrhythmias (AF and flutter) are important
cardiac rhythm disorders in humans (Savelieva and
Camm, 2008b). Drug treatment is widely used, and
inhibition of atrial repolarizing potassium current(s)
is a common approach to suppress arrhythmias by
increasing effective refractoriness (Ehrlich and
1030 British Journal of Pharmacology (2010) 161 1023–1033

Nattel, 2009). In human atrial cells, an important
and tissue-specific potassium current is the ultrarapidly activating outward potassium current (IKur),
which is encoded by KCNA5 (Kv1.5) (Wang et al.,
1993; Li et al., 1996; Nattel et al., 1999). Numerous
studies have demonstrated that the native cardiac
atrial-specific IKur and cloned human cardiac Kv1.5generated current share common biophysical and
pharmacological features (Snyders et al., 1993; Yeola
et al., 1996). Accordingly, KCNA5 is considered a
target for drugs used in the treatment of AF, so our
findings imply that blocking drugs that are also
transporter substrates may display variable efficacy
because of variable transporter function or expression. A number of drugs can produce the nonselective potent blocking action on the KCNA5
channel, besides other (non)cardiac effects, and we
have used some of those drugs here to test the role
of drug transporters, such as quinidine, verapamil,
clofilium, propafenone, 4-AP, erythromycin and
KN-93.

Evidence that KCNA5 block is mediated by
drug interactions with an intracellular site
Atrial repolarization is accomplished through activation of multiple K+ currents, including ITO
(encoded by KCND3), ultra-rapid IKur (encoded by

Drug transporters modulate drug block of cardiac KCNA5 channel

KCNA5), IKr (encoded by KCNH2) and IKs (encoded
by KCNQ1 + KCNE1). Like all voltage-gated potassium channels, the KCNA5 protein complex carrying IKur consists of four a subunits, each with six
transmembrane segments. Inactivation of IKur
occurs via an ‘N-type’ mechanism in which a
b-subunit protein (Kvb1.3) occludes the pore
formed by the tetrameric channel complex (Decher
et al., 2005). The interaction of Kvb1.3 with KCNA5
a-subunits has been shown to competitively
attenuate the effect of KCNA5 antagonists by competitively mimicking N-type inactivation-induced
blockade of the ion channel pore at the intracellular face (Khumar et al., 2004; Decher et al., 2006;
Arias et al., 2007).
Most K+ channel blockers inhibit current by
binding to intracellular site(s), such as internal
mouth of the ion channel pore. In the KCNH2
channel, specific aromatic amino acid residues
lining the intracellular face of the S6 transmembrane domain are critical for drug binding and block
by methanesulfonanilide and other KCNH2 inhibitors (Mitcheson et al., 2000; Chen et al., 2002; Perry
et al., 2004). Similarly, in the KCNA5 channel, residues of the S6 segment facing towards the channel
pore cavity are critical for block by quinidine and
other blocking drugs (Decher et al., 2004; 2006;
Strutz-Seebohm et al., 2007). However, KN-93 suppresses the current through binding to the external
mouth of the KCNA5 channel pore.

Evidence that drug influx and efflux
transporters are present in heart
Variable drug metabolism is a commonly invoked
mechanism underlying variable drug actions.
Given the recognition of specific families of drug
uptake and efflux transporters, extensive studies
have demonstrated that variable transporter function also contributes to variable drug actions (Kim,
2002; 2006; Lee and Kim, 2004). Such variability
may arise from variable transporter expression,
variable function due to polymorphism generating
variable primary amino acid sequences, or drug
interactions inhibiting or enhancing transport
function.
We and others have shown that drug transporters, including OCTN1 and MDR1, are expressed on
the surface of cardiomyocytes. Iwata et al. (2008)
reported that the drug influx transporters OCTN1
and OCTN2 localize on the plasma membrane of
cardiomyocytes from both atrium and ventricle in
mouse heart and mediate uptake of radioactively
labelled quinidine. Since drug blocking sites on
cardiac ion channels are often located intracellularly
(as discussed further below), these data provide
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support for testing the hypothesis that the effects of
drugs that block ion channels may be modulated by
transport molecules for which they are also
substrates.

Modulation of KCNA5 block by OCTN1
and MDR1
We propose two possible mechanisms for the effect
of OCTN1 to potentiate drug block. First, we
propose that OCTN1 accelerates and increases intracellular drug accumulation to facilitate drug access
to the binding site(s) in the inner mouth of the
channel pore, thereby strengthening drug block.
Second, intracellular drug accumulation would also
be predicted to slow dissociation of drug from its
binding site(s) in the channel and thereby further
lead to prolonged block.
For the experiments to test the effect of the
efflux transporter MDR1 on KCNA5 drug block, we
used the antibiotic erythromycin which is both a
channel blocker and an MDR1 substrate. As predicted, the strong KCNA5 inhibition that we
observed with erythromycin was markedly inhibited by MDR1. This result is in good agreement
with our previous study in which MDR1 attenuated inhibition of HERG channel by a potent IKr
blocker ibutilide (McBride et al., 2009b). In these
experiments, we also used the MDR1 inhibitor
reversin-205 to suppress MDR1 activity before
testing the block by erythromycin, and found that
block was restored to the level similar to that seen
in the absence of MDR1 expression. Finally, when
we tested the effect of KN-93, an MDR1 substrate
that blocks KCNA5 from the outside of the cell, we
found no change in the extent of block regardless
of MDR1 expression. This finding supports the
concept that transporter function does not modulate the effects of a blocker acting at the external
aspect of the channel.
In conclusion, in this study, we have shown that
drug-induced block of the atrial-specific KCNA5
channel, responsible for carrying IKur, can be modulated by drug influx and efflux transporters. Accordingly, variability in the action of such drugs may
reflect not only traditionally recognized factors
(such as variable absorption or elimination) but also
variability in these transport processes.

Acknowledgements and funding
This work was supported in part by grants from the
United States Public Health Service (HL46681,
HL49989 and U01HL65962) and The American
Heart Association (0565306B).
British Journal of Pharmacology (2010) 161 1023–1033

1031

BJP

T Yang et al.

Conflict of interest
None.

References
Alexander SPH, Mathie A, Peters JA (2009). Guide to
Receptors and Channels (GRAC), 4th edn. Br J
Pharmacol 158 (Suppl. 1): S1–S254.
Arias C, Guizy M, David M, Marzian S, Gonzalez T,
Decher N et al. (2007). Kvbeta1.3 reduces the degree of
stereoselective bupivacaine block of Kv1.5 channels.
Anesthesiology 107: 641–651.
Chen J, Seebohm G, Sanguinetti MC (2002). Position of
aromatic residues in the S6 domain, not inactivation,
dictates cisapride sensitivity of HERG and eag potassium
channels. Proc Natl Acad Sci U S A 99: 12461–12466.
Decher N, Pirard B, Bundis F, Peukert S, Baringhaus KH,
Busch AE et al. (2004). Molecular basis for Kv1.5
channel block – conservation of drug binding sites
among voltage-gated K+ channels. J Biol Chem 279:
394–400.
Decher N, Kumar P, Gonzalez T, Renigunta V,
Sanguinetti MC (2005). Structural basis for competition
between drug binding and Kvbeta 1.3 accessory
subunit-induced N-type inactivation of Kv1.5 channels.
Mol Pharmacol 68: 995–1005.
Decher N, Kumar P, Gonzalez T, Pirard B,
Sanguinetti MC (2006). Binding site of a novel Kv1.5
blocker: a ‘foot in the door’ against atrial fibrillation.
Mol Pharmacol 70: 1204–1211.
Ehrlich JR, Nattel S (2009). Novel approaches for
pharmacological management of atrial fibrillation.
Drugs 69: 757–774.
Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB,
Ellenbogen KA et al. (2006). ACC/AHA/ESC 2006
Guidelines for the Management of Patients with Atrial
Fibrillation: a report of the American College of
Cardiology/American Heart Association Task Force on
Practice Guidelines and the European Society of
Cardiology Committee for Practice Guidelines (Writing
Committee to Revise the 2001 Guidelines for the
Management of Patients with Atrial Fibrillation):
Developed in Collaboration with the European Heart
Rhythm Association and the Heart Rhythm Society.
Circulation 114: e257–e354.

Hylek EM, Regan S, Go AS, Hughes RA, Singer DE,
Skates SJ (2001). Clinical predictors of prolonged delay
in return of the international normalized ratio to within
the therapeutic range after excessive anticoagulation
with warfarin. Ann Intern Med 135: 393–400.
Iwata D, Kato Y, Wakayama T, Sai Y, Kubo Y, Iseki S
et al. (2008). Involvement of carnitine/organic cation
transporter OCTN2 (SLC22A5) in distribution of its
substrate carnitine to the heart. Drug Metab
Pharmacokinet 23: 207–215.
Khumar P, Gonzalez T, Steinmeyer K, Sanguinetti MC
(2004). Overlapping sites for Kv1.5 drug-binding and
the receptor site for the Kv beta 1.3 inactivation ball.
Biophys J 86: 132A–133A.
Kim RB (2002). Drugs as P-glycoprotein substrates,
inhibitors, and inducers. Drug Metab Rev 34: 47–54.
Kim RB (2006). Transporters and drug discovery: why,
when, and how. Mol Pharm 3: 26–32.
Lee W, Kim RB (2004). Transporters and renal drug
elimination. Annu Rev Pharmacol Toxicol 44: 137–166.
Li GR, Feng J, Wang Z, Fermini B, Nattel S (1996).
Adrenergic modulation of ultrarapid delayed rectifier K+
current in human atrial myocytes. Circ Res 78: 903–915.
McBride BF, Yang T, Liu K, Urban TJ, Giacomini KM,
Kim RB et al. (2009a). The organic cation transporter,
OCTN1, expressed in the human heart, potentiates
antagonism of the HERG potassium channel. J
Cardiovasc Pharmacol 54: 63–71.
McBride BF, Yang T, Roden DM (2009b). Influence of
the G2677T/C3435T haplotype of MDR1 on
P-glycoprotein trafficking and ibutilide-induced block of
HERG. Pharmacogenomics J 9: 194–201.
Milan DJ, Kim AM, Winterfield JR, Jones IL, Pfeufer A,
Sanna S et al. (2009). Drug-sensitized zebrafish screen
identifies multiple genes, including GINS3, as regulators
of myocardial repolarization. Circulation 120: 553–559.
Mitcheson JS, Chen J, Lin M, Culberson C,
Sanguinetti MC (2000). A structural basis for
drug-induced long QT syndrome. Proc Natl Acad Sci U S
A 97: 12329–12333.
Nattel S, Yue L, Wang Z (1999). Cardiac ultrarapid
delayed rectifiers: a novel potassium current family of
functional similarity and molecular diversity. Cell
Physiol Biochem 9: 217–226.
Perry M, de Groot MJ, Helliwell R, Leishman D,
Tristani-Firouzi M, Sanguinetti MC et al. (2004).
Structural determinants of HERG channel block by
clofilium and ibutilide. Mol Pharmacol 66: 240–249.

Grube M, Meyer zu Schwabedissen HE, Prager D,
Haney J, Moritz KU, Meissner K et al. (2006). Uptake of
cardiovascular drugs into the human heart: expression,
regulation, and function of the carnitine transporter
OCTN2 (SLC22A5). Circulation 113: 1114–1122.

Rampe D, Murawsky MK (1997). Blockade of the human
cardiac K+ channel Kv1.5 by the antibiotic
erythromycin. Naunyn Schmiedebergs Arch Pharmacol
355: 743–750.

Hariharan S, Gunda S, Mishra GP, Pal D, Mitra AK
(2009). Enhanced corneal absorption of erythromycin
by modulating p-glycoprotein and MRP mediated efflux
with corticosteroids. Pharm Res 26: 1270–1282.

Rampe D, Wible B, Fedida D, Dage RC, Brown AM
(1993). Verapamil blocks a rapidly activating delayed
rectifier K+ channel cloned from human heart. Mol
Pharmacol 44: 642–648.

1032 British Journal of Pharmacology (2010) 161 1023–1033

Drug transporters modulate drug block of cardiac KCNA5 channel

Rezazadeh S, Claydon TW, Fedida D (2006). KN-93
(2-[N-(2-hydroxyethyl)]-N-(4-methoxybenzenesulfonyl)]
amino-N-(4-chlorocinn amyl)-N-methylbenzylamine), a
calcium/calmodulin-dependent protein kinase II
inhibitor, is a direct extracellular blocker of
voltage-gated potassium channels. J Pharmacol Exp Ther
317: 292–299.
Riganti C, Campia I, Polimeni M, Pescarmona G,
Ghigo D, Bosia A (2009). Digoxin and ouabain induce
P-glycoprotein by activating calmodulin kinase II and
hypoxia-inducible factor-1alpha in human colon cancer
cells. Toxicol Appl Pharmacol 240: 385–392.
Savelieva I, Camm J (2008a). Anti-arrhythmic drug
therapy for atrial fibrillation: current anti-arrhythmic
drugs, investigational agents, and innovative
approaches. Europace 10: 647–665.
Savelieva I, Camm J (2008b). Update on atrial
fibrillation: part I. Clin Cardiol 31: 55–62.
Seebohm G, Pusch M, Chen J, Sanguinetti MC (2003).
Pharmacological activation of normal and
arrhythmia-associated mutant KCNQ1 potassium
channels. Circ Res 93: 941–947.
Sharom FJ, Yu X, Lu P, Liu R, Chu JW, Szabo K et al.
(1999). Interaction of the P-glycoprotein multidrug
transporter (MDR1) with high affinity peptide
chemosensitizers in isolated membranes, reconstituted
systems, and intact cells. Biochem Pharmacol 58:
571–586.
Sikri V, Pal D, Jain R, Kalyani D, Mitra AK (2004).
Cotransport of macrolide and fluoroquinolones, a
beneficial interaction reversing P-glycoprotein efflux.
Am J Ther 11: 433–442.

BJP

Snyders DJ, Tamkun MM, Bennett PB (1993). A rapidly
activating and slowly inactivating potassium channel
cloned from human heart. Functional analysis after
stable mammalian cell culture expression. J Gen Physiol
101: 513–543.
Strutz-Seebohm N, Gutcher I, Decher N, Steinmeyer K,
Lang F, Seebohm G (2007). Comparison of potent Kv1.5
potassium channel inhibitors reveals the molecular basis
for blocking kinetics and binding mode. Cell Physiol
Biochem 20: 791–800.
Thom T, Haase N, Rosamond W, Howard VJ,
Rumsfeld J, Manolio T et al. (2006). Heart Disease and
Stroke Statistics – 2006 Update: a report from the
American Heart Association Statistics Committee and
Stroke Statistics Subcommittee. Circulation 113:
e85–151.
Wang Z, Fermini B, Nattel S (1993). Sustained
depolarization-induced outward current in human atrial
myocytes. Evidence for a novel delayed rectifier K+
current similar to Kv1.5 cloned channel currents. Circ
Res 73: 1061–1076.
Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A,
Shimane M et al. (1999). Novel membrane transporter
OCTN1 mediates multispecific, bidirectional, and
PH-dependent transport of organic cations. J Pharmacol
Exp Ther 289: 768–773.
Yeola SW, Rich TC, Uebele VN, Tamkun MM,
Snyders DJ (1996). Molecular analysis of a binding site
for quinidine in a human cardiac delayed rectifier K+
channel. Role of S6 in antiarrhythmic drug binding.
Circ Res 78: 1105–1114.

British Journal of Pharmacology (2010) 161 1023–1033

1033

